Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the ...
Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant ad...
Investor optimism in biotech has increased due to the expected lowering of inter...
J&J has made its second dermatology deal this month, adding Numab’s bispecific a...
Logistics service providers (LSPs) can help pharma companies achieve their suppl...
Nearly 37% of subjects experienced serious treatment-emergent adverse events, wi...
A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Ke...
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan,...
Shares in Merus rose by 15% in premarket trading, following the announcement of ...
Shares in the pharma company rose 40% in premarket trading.
The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile o...
Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financin...
Affecting more than 162,000 patients worldwide, global clinical trials are resea...
The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference ...
Biocon has entered an exclusive licence and supply agreement with Handok to comm...
In this issue: Lula's progress plan for Brazil, tracking opioid lawsuit settleme...
